Compare NTCT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | OCUL |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1999 | 2014 |
| Metric | NTCT | OCUL |
|---|---|---|
| Price | $42.92 | $8.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $31.00 | $23.56 |
| AVG Volume (30 Days) | 528.6K | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.39 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $891,820,000.00 | $1,990,000.00 |
| Revenue This Year | $6.02 | $7.93 |
| Revenue Next Year | $2.55 | $96.07 |
| P/E Ratio | $31.90 | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $20.40 | $6.23 |
| 52 Week High | $42.37 | $16.44 |
| Indicator | NTCT | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 72.45 | 49.39 |
| Support Level | $26.16 | $8.36 |
| Resistance Level | N/A | $9.93 |
| Average True Range (ATR) | 1.32 | 0.42 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 99.32 | 57.35 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.